Skip to main content
. Author manuscript; available in PMC: 2019 Jul 15.
Published in final edited form as: Clin Cancer Res. 2018 Apr 10;24(14):3433–3446. doi: 10.1158/1078-0432.CCR-17-2793

Figure 6. Patients with above-median expression of the 74-gene GR activity signature (GRsig) have significantly decreased relapse-free survival.

Figure 6.

Genes in the GRsig were selected from among the n=462 tumor-relevant and antagonist-reversed Dex-regulated genes based on their univariate association with RFS in the Discovery cohort (HR ≥1.5 or HR ≤0.67; and p < 1e-5). (A) Summary of GRsig genes (top line) and their Dex-mediated up- and downregulation, and the subset of GRsig genes that are putative direct GR target genes (middle line) with loss of GR peak with Dex/antagonist treatment (bottom line). (B) List of individual GRsig genes, separated by their Dex-mediated up- or down-regulation with bolded gene names indicating putative direct GR target genes. (C, D) Kaplan-Meier estimates showing that the above-median GRsig expression (versus all others) is associated with RFS in both the Discovery and Validation cohorts.